Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
NEW YORK, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
Mr. Bentsur's presentation will take place on Tuesday, November 18, at 10:20 a.m. ET.
A live audio webcast of Mr. Bentsur's presentation will be accessible within the Investor Relations section of the Company's website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's lead product, Ferric Citrate, was approved by the U.S. Food and Drug Administration on September 5, 2014.
For additional company information, including full prescribing information for Ferric Citrate, please visit www.keryx.com.
CONTACT: KERYX CONTACT: Amy Sullivan Vice President, Corporate Development and Public Affairs Tel: 617.466.3447 e-mail: [email protected]Source: Keryx Biopharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Truecanhelp Unveils New CRS Score Calculator to Enhance the Canadian Immigration Process
- Green Energy Park Raises 30 million US Dollars in Initial Equity Funding to Accelerate the Energy Transition and to Build One of the Largest Renewable Hydrogen Production and Export Terminal Facilitie
- CTT Systems AB (publ.) - Interim Report First Quarter 2024
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!